FDA Will Apply the " Uncanny Valley " Hypothesis to Test the " Eeriness " of Animated Characters in Drug Ads

AbbVie, Astrazeneca, Eli Lilly, GSK, Merck, Regeneron Pharmaceuticals, plus others have submitted comments to the FDA regarding its plans to research animated spokes-characters in DTC Drug Ads (see Federal RegisterDocket ID: FDA-2016-N-0538).Merck was not impressed: “While the proposed collection of information may be interesting to learn, it may not have practical utility for the general public and may be unnecessary for the proper performance of FDA's functions. ”Regeneron expressed a similar concern; i.e.,"the results from this study should not be used to guide or influence FDA's current thinking on the use of animation in DTC ads."But FDA is sticking to its guns.“On the contrary,” says FDA in response, “this particular study has the potential to directly influence policy in an area that we have no prior research on. Although one research study cannot answer all questions, we believe we have designed the study in such a way that we will be able to pro vide information on the issue of animation in DTC ads. Because there is no previous research of this kind, this will be an informative study that will help FDA develop guidance and policy in the future, should the research reveal a need to.”Meanwhile, The Advertising Coalition, representing national trade associations whose members prepare and deliver advertising through television, newspapers, magazines, the Internet, whipped out its 1st Amendment gun: “[T]his study must be viewed through the...

Source: Pharma Marketing Blog - October 28, 2016 Category: Pharmaceuticals Tags: Animation DTC Advertising FDA Study Source Type: blogs